International Journal of Infectious Diseases (Mar 2022)

Screening for hepatocellular carcinoma among adults with HIV/HBV co-infection in Zambia: a pilot study

  • C. Riebensahm,
  • H. Chitundu,
  • G. Muula,
  • B. Chihota,
  • E. Sinkala,
  • V. Sunkutu,
  • M.H. Maurer,
  • J.F. Dufour,
  • A. Berzigotti,
  • M. Egger,
  • C. Bolton-Moore,
  • M. Vinikoor,
  • G. Wandeler

Journal volume & issue
Vol. 116
pp. 391 – 396

Abstract

Read online

ABSTRACT: Background and aims: Chronic hepatitis B virus (HBV) infection is the main cause of hepatocellular carcinoma (HCC) in sub-Saharan Africa (SSA). An HCC screening initiative was piloted in an established cohort of individuals co-infected with human immunodeficiency virus (HIV) and HBV on antiretroviral therapy (ART) at two outpatient clinics in Lusaka, Zambia. Methods: All patients underwent abdominal ultrasound (AUS) and transient elastography. Results: Among 279 patients co-infected with HIV/HBV, 165 (59.1%) were men, median age was 34 years [interquartile range (IQR) 28–39 years] and median CD4 count was 246 cells/µL (IQR 112–355 cells/µL) at ART initiation. While 102 (55.7%) individuals had elevated transaminases, 114 (59.7%) had HBV levels >2000 IU/mL and 59 (24.6%) had significant fibrosis. At their first AUS measurement, 75 (26.9%) participants had hepatomegaly and 69 (24.7%) had periportal fibrosis. Five patients had a liver lesion >1 cm, an indication for confirmatory imaging. Conclusions: In one of the first HCC screening initiatives in SSA, 2% of patients co-infected with HIV/HBV had significant liver lesions, and one-quarter had findings suggestive of schistosomiasis-induced liver damage.

Keywords